Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Abeona Therapeutics, Brammer Bio Form Collaboration | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Abeona Therapeutics, Brammer Bio Form Collaboration

Tie-up to focus on commercial AAV process development, scale up and assay validation

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Abeona Therapeutics has updated its manufacturing strategy and plans for ABO-102, including strategic manufacturing commitments with Brammer Bio for commercial translation. The clinical stage biopharma company also appointed Phillip Maples, vice president of therapeutic development and quality management to oversee all cell-therapy manufacturing and Adam Davis as director to oversee AAV manufacturing.

“Our autologous cell and gene therapy programs continue to demonstrate remarkable effects in clinical trials of patients with life-threatening diseases with no treatment options, and we are pleased to collaborate with Brammer Bio for commercial AAV process development, scale up and assay validation for clinical programs and internal capabilities,” said Timothy Miller, president and chief executive officer, Abeona. “Dr. Maples’ technical, manufacturing, regulatory and quality management expertise makes him a natural fit to supervise our manufacturing efforts.  We are pleased with the progress so far and look forward to providing a more fulsome update at our inaugural Research and Development day, October 11 in New York City.”

Richard Snyder, chief scientific officer, Brammer Bio, said, “Brammer Bio is delighted to be able to support Abeona with process development and clinical vector supply based on over a decade of experience in cGMP manufacturing using AAV gene transfer vectors on a variety of platforms.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics